Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs EPR Properties (EPR) Price & Performance

Ascendis Pharma A/STrade
EPR PropertiesTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs EPR Properties — how do they compare? Ascendis Pharma A/S trades at $255.52 (market cap $16.67B), while EPR Properties trades at $60.34 (market cap $4.58B). The key difference: Ascendis Pharma A/S is far larger — about 3.6× EPR Properties's market cap, and EPR Properties pays a 6.22% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDEPR
Market Cap
$16.67B$4.58B
Sector
HealthReal Estate
52-Week High
$277.18$64.32
52-Week Low
$189.74$48.71
Enterprise Value
$17.04B$8.09B
Dividend Yield
6.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.

ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.

EPR Properties

EPR Properties trades at $60.32, down 0.13% recently, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 results, beating FFO estimates, and raised full-year guidance. Revenue grew to $699 million in 2026, though net income dipped to $263 million. Analysts maintain a consensus price target of $65.30, with 27% buy ratings, but technical indicators suggest near-term pressure.

The outlook is mixed: fundamental strength from dividend growth and acquisitions supports long-term value, but technical bearishness and elevated valuation ratios pose risks. Investors should weigh the 6% dividend yield against potential volatility from interest rate sensitivity and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR